File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum

TitleAssessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
Authors
Issue Date2002
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2002, v. 97 n. 4, p. 489-492 How to Cite?
AbstractWe have evaluated the performance of 3 new EBV ELISA for the diagnosis of nasopharyngeal carcinoma (NPC). The tests were specific for EBNA I IgA, EBNA I IgG and zta IgG, respectively. Their distinct antigenic specificity permits these assays to be used in concert in an approach that differentiates patients and apparently healthy subjects on the basis of their antibody spectrum. By so exploiting a distinguishing feature of NPC first described by the late Werner Henle that the patients sustain high levels of a broad spectrum of serum EBV antibodies, this approach achieved a sensitivity of 92% and a specificity of 93%, surpassing the performance of each of these assays individually. The enhanced performance is especially useful in population screening. It was shown that relative risk of N PC sustained by apparently healthy subjects residing in a high incidence area for NPC in the Pearl River estuary in Southern China may vary according to EBV antibody spectrum. The risk of the cancer was markedly reduced with odds ratios of 0.009 for 59% of those who had low level of all 3 antibodies. The risk was increased as antibody spectrum broadens and the risk was the highest with an odds ratio of 138 for 0.4% of those who had high levels of all 3 antibodies. Thus, EBV antibody spectrum may serve to guide follow-up measures for early detection of the cancer and/or risk counseling according to level of the risk of the cancer sustained by the screened individuals. © 2002 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/78816
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.657
ISI Accession Number ID
References
Errata

 

DC FieldValueLanguage
dc.contributor.authorCheng, WMen_HK
dc.contributor.authorChan, KHen_HK
dc.contributor.authorChen, HLen_HK
dc.contributor.authorLuo, RXen_HK
dc.contributor.authorNg, SPen_HK
dc.contributor.authorLuk, Wen_HK
dc.contributor.authorZheng, BJen_HK
dc.contributor.authorJi, MFen_HK
dc.contributor.authorLiang, JSen_HK
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorWang, DKen_HK
dc.contributor.authorZong, YSen_HK
dc.contributor.authorNg, MHen_HK
dc.date.accessioned2010-09-06T07:47:09Z-
dc.date.available2010-09-06T07:47:09Z-
dc.date.issued2002en_HK
dc.identifier.citationInternational Journal Of Cancer, 2002, v. 97 n. 4, p. 489-492en_HK
dc.identifier.issn0020-7136en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78816-
dc.description.abstractWe have evaluated the performance of 3 new EBV ELISA for the diagnosis of nasopharyngeal carcinoma (NPC). The tests were specific for EBNA I IgA, EBNA I IgG and zta IgG, respectively. Their distinct antigenic specificity permits these assays to be used in concert in an approach that differentiates patients and apparently healthy subjects on the basis of their antibody spectrum. By so exploiting a distinguishing feature of NPC first described by the late Werner Henle that the patients sustain high levels of a broad spectrum of serum EBV antibodies, this approach achieved a sensitivity of 92% and a specificity of 93%, surpassing the performance of each of these assays individually. The enhanced performance is especially useful in population screening. It was shown that relative risk of N PC sustained by apparently healthy subjects residing in a high incidence area for NPC in the Pearl River estuary in Southern China may vary according to EBV antibody spectrum. The risk of the cancer was markedly reduced with odds ratios of 0.009 for 59% of those who had low level of all 3 antibodies. The risk was increased as antibody spectrum broadens and the risk was the highest with an odds ratio of 138 for 0.4% of those who had high levels of all 3 antibodies. Thus, EBV antibody spectrum may serve to guide follow-up measures for early detection of the cancer and/or risk counseling according to level of the risk of the cancer sustained by the screened individuals. © 2002 Wiley-Liss, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_HK
dc.relation.ispartofInternational Journal of Canceren_HK
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAntibodies, Viral - blood - immunologyen_HK
dc.subject.meshAntigens, Viral - immunologyen_HK
dc.subject.meshBiological Markersen_HK
dc.subject.meshCarcinoma - diagnosis - epidemiology - immunology - virologyen_HK
dc.subject.meshChina - epidemiologyen_HK
dc.subject.meshDNA-Binding Proteins - immunologyen_HK
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_HK
dc.subject.meshEpstein-Barr Virus Infections - epidemiology - immunologyen_HK
dc.subject.meshEpstein-Barr Virus Nuclear Antigens - immunologyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFluorescent Antibody Technique, Indirecten_HK
dc.subject.meshHerpesvirus 4, Human - immunologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunoglobulin A - blood - immunologyen_HK
dc.subject.meshImmunoglobulin G - blood - immunologyen_HK
dc.subject.meshIncidenceen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNasopharyngeal Neoplasms - diagnosis - epidemiology - immunology - virologyen_HK
dc.subject.meshOdds Ratioen_HK
dc.subject.meshRisken_HK
dc.subject.meshSensitivity and Specificityen_HK
dc.subject.meshSeroepidemiologic Studiesen_HK
dc.subject.meshTrans-Activators - immunologyen_HK
dc.subject.meshViral Proteinsen_HK
dc.titleAssessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrumen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0020-7136&volume=97:&spage=489&epage=492.&date=2002&atitle=Assessing+the+risk+of+nasopharyngeal+carcinoma+on+the+basis+of+EBV+antibody+spectrum.en_HK
dc.identifier.emailChen, HL:hlchen@hkucc.hku.hken_HK
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_HK
dc.identifier.authorityChen, HL=rp00383en_HK
dc.identifier.authorityZheng, BJ=rp00353en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/ijc.1641en_HK
dc.identifier.pmid11802211-
dc.identifier.scopuseid_2-s2.0-0036466882en_HK
dc.identifier.hkuros106061en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036466882&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume97en_HK
dc.identifier.issue4en_HK
dc.identifier.spage489en_HK
dc.identifier.epage492en_HK
dc.identifier.isiWOS:000173078800013-
dc.publisher.placeUnited Statesen_HK
dc.relation.erratumeid:eid_2-s2.0-0037140080-
dc.relation.erratumdoi:10.1002/ijc.10383-
dc.identifier.scopusauthoridCheng, WM=23101970500en_HK
dc.identifier.scopusauthoridChan, KH=7406034307en_HK
dc.identifier.scopusauthoridChen, HL=26643315400en_HK
dc.identifier.scopusauthoridLuo, RX=7202671104en_HK
dc.identifier.scopusauthoridNg, SP=8862966400en_HK
dc.identifier.scopusauthoridLuk, W=7005237837en_HK
dc.identifier.scopusauthoridZheng, BJ=7201780588en_HK
dc.identifier.scopusauthoridJi, MF=8229413000en_HK
dc.identifier.scopusauthoridLiang, JS=16145038900en_HK
dc.identifier.scopusauthoridSham, JST=7101655565en_HK
dc.identifier.scopusauthoridWang, DK=7407072857en_HK
dc.identifier.scopusauthoridZong, YS=7005203474en_HK
dc.identifier.scopusauthoridNg, MH=7202076421en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats